XORTX Therapeutics Inc (TSE:XRTX) has released an update.
XORTX Therapeutics Inc. has launched a precision medicine program to develop diagnostics and treatments for kidney disease and other conditions by targeting genetic factors linked to xanthine oxidase over-expression. This innovative approach aims to create tailored treatments for subpopulations of patients with common genetic susceptibilities, potentially improving therapeutic outcomes.
For further insights into TSE:XRTX stock, check out TipRanks’ Stock Analysis page.